We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd | NYSE:TAK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.25 | 1.91% | 13.36 | 4,280 | 11:52:41 |
From May 2023 to May 2024
By Ben Glickman
Takeda has received approval from the U.S. Food and Drug Administration for ENTYVIO as a therapy for adults with moderate to severe ulcerative colitis.
The Osaka, Japan-based pharmaceutical company said it expected ENTYVIO to be available in the U.S. as a single-dose pen by the end of October.
The company currently is waiting for a response from the FDA on a biologics license application for administering ENTYVIO in the treatment of adults with Crohn's disease.
Takeda does not expect the approval to affect full-year forecasts for the company's results.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 27, 2023 16:58 ET (20:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Takeda Pharmaceutical Chart |
1 Month Takeda Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
